Drug Pricing & Pharmacy Benefit

Synthesis:

In the last 24 hours, there have been no direct announcements or policy changes from CMS or HHS leadership regarding drug pricing or pharmacy benefit reforms relevant to value-based care stakeholders. The most directly related development comes from the policy discourse surrounding the upcoming American Hospital Association (AHA) Annual Membership Meeting, which is expected to address payment, regulatory, and market pressures—including drug costs—impacting hospitals’ ability to engage in population health and value-based contracts (AHA Annual Membership Meeting: Three Issues that Require Attention). Other recent publications largely focus on issues tangential to U.S. value-based drug pricing, such as international device markets and broader public health lobbying, with no substantive updates on U.S. Medicare, Medicaid, ACO, or pharmacy benefit payment transformation in the last 24 hours.